SASSARI, Italy & PRINCETON, N.J.--()--ViroStatics, srl today announced the Company’s President and CEO, Dr. Franco Lori, will be speaking at the HIV DART 2008 conference in Puerto Rico on Wednesday, December 10th. Dr. Lori’s presentation, “Development of VS411, a Virostatic Drug Fixed Dose Combination (FDC) Designed to Inhibit Both HIV and Immune Hyperactivation,” will highlight the final results from the Company’s Phase I study of its lead product for the treatment of HIV disease, VS411. In addition, Dr. Lori will discuss the Company’s Phase II development program for VS411 as well as recent advancements in ViroStatics’ drug discovery program.
“Development of VS411, a Virostatic Drug Fixed Dose Combination (FDC) Designed to Inhibit Both HIV and Immune Hyperactivation”
About HIV DART 2008
The focus of this influential meeting is to assemble clinicians, researchers and basic scientists together to advance knowledge of the ongoing drug development processes in antiretroviral research. HIV DART 2008 uniquely blends the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for HIV infection.
ViroStatics srl, an Italian pharmaceutical company with operations in Sassari and Pavia, Italy and Princeton, NJ, USA is committed to discovering and developing novel combination therapeutics to address significant medical needs in HIV/AIDS, chronic infections and related fields. The company is developing its lead product, VS411, as the first fixed-dose combination of two drugs that not only decrease HIV replication but also protect and conserve the immune system. VS411 has completed Phase I and is now undergoing evaluation in a multinational Phase II development program. ViroStatics has also developed novel biomarker assays and a proprietary screening methodology to rapidly and efficiently identify cytostatic agents with potential to inhibit viral replication and control the over-stimulation of the immune system that is believed to drive the progression of HIV to AIDS. ViroStatics is committed to expanding its pipeline and product portfolio by in-licensing early- and late-stage compounds and exploring co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals.